Masatoshi Omoto

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

NMO sera down-regulate AQP4 in human astrocyte and induce cytotoxicity independent of complement

Hiroyo Haruki, Fumitaka Shimizu, Masatoshi Omoto et al. · Journal of the Neurological Sciences · 2013 · 46 citations

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

Jacqueline Palace, Dean M. Wingerchuk, Kazuo Fujihara et al. · Multiple Sclerosis and Related Disorders · 2020 · 37 citations · Full text

Sera from patients with multifocal motor neuropathy disrupt the blood-nerve barrier

Fumitaka Shimizu, Masatoshi Omoto, Yasuteru Sano et al. · Journal of Neurology Neurosurgery & Psychiatry · 2013 · 36 citations

Pathological study on amyloidosis in Cygnus olor (mute swan) and other waterfowl

Shinsuke Tanaka, Dan Cui, Hiroo Kawano et al. · Medical Molecular Morphology · 2008 · 30 citations

Biology, Other Waterfowl, Mute Swan +1